$BTAI
Прорывная терапия ))
Ну хоть первая хорошая новость, может ниже падать не будем...
On August 22, 2023, BioXcel Therapeutics, Inc. (“BTAI” or the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) had granted the Company a Type B/Breakthrough guidance meeting regarding the Company’s TRANQUILITY clinical trial program, which is scheduled for October 11, 2023.